Question 1

How much did Scancell Holdings raise in its July 24, 2026 AIM placing?

Accepted Answer

Scancell Holdings raised gross proceeds of about £13.0m (about $17.4m) by upsizing a UK placing that issued 144.44m new shares on AIM after the initial ~£9.0m target was very significantly oversubscribed.

Question 2

What deadline did Scancell set for completing its proposed Neuphoria merger and related financing?

Accepted Answer

Scancell said completion is targeted for 28 February 2027, subject to approvals, Nasdaq clearance and raising at least $75 million through the financing.

Question 3

When did Scancell obtain UK regulatory authorisation for its Phase 3 iSCIB1+ trial in advanced melanoma?

Accepted Answer

Scancell obtained UK regulatory authorisation in August 2026 for its Phase 3 registrational trial of iSCIB1+ in advanced melanoma.

Question 4

What did Scancell report for its operating loss for the year ended 30 April?

Accepted Answer

For the year ended 30 April, Scancell reported an operating loss of £17.4m, up from £15.0m.

Question 5

What material uncertainty did Scancell’s auditors flag about going concern?

Accepted Answer

Scancell’s auditors flagged a material uncertainty over going concern, saying that excluding still-conditional Neuphoria merger and financing proceeds, the company lacks sufficient committed funding for the next 12 months.

Question 6

What retail offer did Scancell Holdings launch via the Winterflood Retail Access Platform on July 24, 2026?

Accepted Answer

Scancell launched a retail offer via the Winterflood Retail Access Platform to raise up to about £2.3m (about $3.0m) at the same placement price, expected to close at 4:30pm on 24 July with results due by 7am on 27 July.

Timeline

Scancell

Scancell widens annual loss

Scancell wins MHRA clearance for Phase 3 melanoma trial

Scancell to merge with Neuphoria in Nasdaq listing and $89m financing

More in Biotech

Genflow wins Japanese patent allowance for SIRT6 therapy

Sareum signals intention to launch equity capital raise

OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial

Poolbeg Pharma secures South Korean patent for POLB 001

Avacta raises £12.5m in placing and subscription

Health & Bio Today: Fusion Antibodies refreshes platform after margin turnaround, Molecule Group

Fusion Antibodies relaunches website to sharpen customer focus

Cardiogeni shares suspended on delayed annual accounts

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

Eden Research wins US label expansion for Mevalone

GENinCode revenue halves as NHS cutbacks bite

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer